NCT04309578招募中2 期
A Phase II Clinical Study of Trastuzumab in Combination With Capecitabine and Cisplatin (XP) in Patients With Tissue HER2-negative But Serum HER2-positive Advanced Gastric Cancer: XP+Samfenet
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Efficacy (Overall tumor response)
研究概览
简要总结
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancer
详细描述
3-weekly/ 1cycle treatment
- Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks
- Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)
- Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with inoperable, locally-advanced or recurrent and/or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who are not eligible for curative therapy and are histologically diagnosed.
- •Diseases measurable according to Response Evaluation Criteria in Solid Tumors (RECIST1.1) using imaging technique (CT or MRI).
- •Tissue HER2-negative tumors (primary or metastatic tumors) defined as IHC2+ and FISH- or IHC 0 or 1+ according to gastric cancer assessment system for HER2 (see Annex 12.5).
- •ECOG Performance status 0, 1 or 2 (see Annex 12.1).
- •Survival for at least 3 months should be possible.
- •Appropriate bone marrow, renal, and hepatic functions. General inclusion criteria
- •Males or females aged 19 years.
- •Patients should sign the informed consent form (ICF).
排除标准
- •Patients who previously received chemotherapy for advanced/metastatic diseases (adjuvant/neoadjuvant chemotherapy, completed at least 6 months prior to enrollment in this clinical study, is permitted, but platinum-based adjuvant/neoadjuvant chemotherapy is not permitted).
- •Patients with a lack of physical integration of the upper gastrointestinal tract or with a malabsorption syndrome (e.g., patients who underwent partial or total gastric resection can participate in this clinical study, but patients equipped with a jejunostomy tube cannot participate).
- •Patients with active (serious or uncontrolled) gastrointestinal bleeding.
- •Patients with relevant toxicities remaining following previous curative therapy (except for alopecia). For example, neurotoxicity ≥ grade 2 based on NCI-CTCAE version 5.
- •Patients with a history of other malignant diseases based on the date of complete recovery within 5 years prior to the initiation of treatment in this clinical study (except for in-situ cervical cancer and basal cell carcinoma).
- •Hematologic, blood chemistry, and organ functions
- •Neutrophil count < 1.5 × 109/L, or platelet count < 100 × 109/L.
- •Serum bilirubin> 1.5 × upper limit of normal (ULN); or AST or ALT > 2.5 × ULN (or > 5 × ULN hepatic metastasis patients); or alkaline phosphatase > 2.5 × ULN (or > 5 × ULN hepatic metastasis patients, or > 10 × ULN hepatic metastasis-free bone metastasis patients); or, albumin < 2.5 g/dL.
- •Creatinine clearance < 60 mL/min. However, creatinine clearance is first calculated using the Cockroft-Gault formula, and if the value is < 60ml/min, a 24hr urine collection test is carried out. Subject enrollment is possible only when creatinine clearance is ≥ 60mL/min.
- •Other investigational product-associated exclusion criteria
- •History of proven congestive heart failure; angina pectoris in need of medication; evidence of transmural myocardial infarction through electrocardiogram (ECG); uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 100 mmHg); clinically significant heart valve disorders; and high-risk uncontrolled arrhythmia.
- •Baseline left ventricular ejection fraction (LVEF) < 50% (measured with echocardiogram or MUGA).
- •Patients with dyspnoea at rest due to advanced tumors or other diseases, or who need an adjuvant oxygen therapy.
- •Patients who are treated with long-term or high-dose corticosteroids (steroid inhalation or short-term use of oral steroids for vomiting inhibition and appetite stimulation is permitted).
- •Patients with Clinically significant hypoacusis
- •Patients known to show dihydropyrimidine dehydrogenase (DPD) deficiency. General exclusion criteria
- •Patients with a history of brain metastasis or clinical evidence.
- •Uncontrolled serious systemic intercurrent diseases (e.g., infection or uncontrolled diabetes).
- •Females who are pregnant or are breast-feeding.
- •Fertile males and females who are unwilling to use effective contraceptive methods.
- •Patients who are treated with another investigational product within 4 weeks prior to the initiation of treatment in this clinical study.
- •Patients receiving radiation therapy within 4 weeks prior to the initiation of treatment with the study drug (palliative radiation curative therapy that is partially carried out for bone metastasis. Washout period of 2 weeks is also permitted in patients recovered from all acute toxicities.).
- •Patients who underwent major surgery within 4 weeks prior to the initiation of treatment with the study drug and have not yet been completely recovered.
- •Patients known to have HIV infectivity or active infection with HBV or HCV.
- •Patients with hypersensitivity to the study drug.
研究组 & 干预措施
treatment arm
Experimental
Single arm
干预措施: Trastuzumab, Capecitabine and Cisplatin (Drug)
结局指标
主要结局
Efficacy (Overall tumor response)
时间窗: 2 years
Overall tumor response (responder/non-responder) which is a primary efficacy endpoint: is defined as the maximal response among confirmed cases of complete response (CR) or partial response (PR) determined by definite radiological assessment of target and nontarget lesions in accordance with RECIST criteria version 1.1.
次要结局
- Overall Survival(2 years)
- Time to disease progression(2 years)
- Safety(Toxicity profile)(2 years)
- Duration of response(2 years)
- progression free survival(2 years)
研究者
Min-Hee Ryu
Professor
Asan Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterSquamous Cell Carcinoma of the BladderStage IV Bladder CancerTransitional Cell Carcinoma of the BladderNCT00005831National Cancer Institute (NCI)40
已完成
2 期
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast CancerBreast CancerNCT00297596SCRI Development Innovations, LLC25
Unknown
2 期
A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerGastric CancerNCT01228045National University Hospital, Singapore30
已完成
2 期
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOXMetastatic or Recurrent Gastric AdenocarcinomaHer-2 Positive Gastric CancerNCT01396707Asan Medical Center55
Unknown
2 期
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 TherapiesMetastatic Breast CancerNCT02238509Consorzio Oncotech154